EMMET BROWNE
November 2017

All information presented herein is subject to confidentiality agreements and not for onward distribution unless express consent given.
Our Mission

Improving the lives of billions of people worldwide through the predicted discovery of Bioactive Peptides
Global & worsening health crisis...

Uniquely discovering bioactive peptides with an incredible array of health benefits... and more to come

NURITAS

Global disease epidemic
Ageing population
Burgeoning costs
Growing population
Traditional drug therapies untargeted
Heightened consumer awareness

Anti-inflammatory
Anti-diabetes
Muscle recovery & growth
Anti-oxidation
Cardiovascular health
Anti-aging
Oncology
Nature has provided
the solution
Pioneering a step-change in peptide discovery

Traditional discovery methods

- Time consuming: 5-7 YEARS
- Inefficient: 0.1% CHANCE
- Incredibly expensive: €35 + MILLION

The Nuritas Way

Based on Artificial Intelligence
Nuritas: The solution
Pioneering a step-change in peptide discovery

Traditional discovery methods

- Time consuming: 5-7 YEARS
- Inefficient: 0.1% CHANCE
- Incredibly expensive: €35 + MILLION

The Nuritas Way

- Unrivalled speed: 10X FASTER*
- More accurate: 500X MORE*
- Cost efficient: LESS EXPENSIVE*

*Efficiency improving consistently

nuritas.com
Confidential
>$1 trillion global market opportunities-
Our patented peptides have a role in each

Pharmaceuticals
Functional Food
Nutrition & Supplements
Medical Food
Dermatology
Plant Health
Animal Health
3. Glucose Regulation
Global Projections for the Diabetes Epidemic 2003-2025

WORLD
2003=194M
2025=333M
↑ 72%

23M
36.2M
↑ 57%

48.4M
58.6M
↑ 21%

19.2M
39.4M
↑ 105%

39.3M
81.6M
↑ 108%

43.0M
75.8M
↑ 79%

14.2M
26.2M
↑ 85%

7.1M
15.0M
↑ 111%
415 million (333) people have type 2 diabetes worldwide. Europe has 60 million (59). Diabetes swallows 13% of the EU healthcare budget (€290bn).
Nuritas Retain and Develop LIVE example – Solving the global diabetes epidemic...

“Nuritas awarded €3m EU grant to commercialise a peptide for the fight against Type 2 diabetes”
Pre Diabetes Ingredient

Pre-Clinical In vitro testing: Sample Results
Pre Diabetes Ingredient / Asset (1 of 2 peptide networks)

Figure 3: Glucose uptake in Human Skeletal Muscle Cells

1μM insulin = 5.807 μg/ml
Pre Diabetes Ingredient

Pre-Clinical In vivo testing: Sample Results
Pre Diabetes Ingredient / Asset (1 of 2 peptide networks)

Overall Nuritas Peptides decrease HbA1c by 1.1%

A 1% reduction in HbA1c translates to:\(^1\):

- Diabetes-related deaths by 21%
- Risk of microvascular complications by 37%
- Myocardial infarction by 14%

\(^1\) Bonora E, et al. Diabetes; 47:1643–1649
What H2020 grant meant to Nuritas

November 2017
Our Mission

Improving the lives of billions of people worldwide through the predicted discovery of Bioactive Peptides